OLIPASS Q1 2026 Report: Max Shareholder Change
올리패스
244460
Signal Score
Historical Avg Return (5d)
-0.18%
Data Coverage
100%n=3385
Risk-adjusted indicator based on 3385 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • Max Shareholder Change: Invest Partners 1 to GenoCure (2025.11.21)
- • GenoCure Shareholding (2025.11.22): 1,909,220 Shares (28.60%)
- • GenoCure Shareholding (2025.12.08): 31.4% (due to 3rd party capital increase)
- • OLIPASS 2 Preferred Stock (Current): 10,604 Shares (499,978,600 KRW)
- • OLIPASS 3 Preferred Stock (Current): 24,154 Shares (503,610,900 KRW)
- • PDRN Global Market Size (2022): 5.69T KRW
- • PDRN Global Market Size (2024 Forecast): 9.78T KRW
AI Analysis Summary
OLIPASS Corporation's Q1 2026 Quarterly Report primarily details changes in major shareholders and outlines new business objectives. The maximum shareholder changed from Invest Partners 1 to GenoCure on November 21, 2025, with GenoCure's stake increasing to 31.4% by December 8, 2025, due to a third-party capital increase. The company has added numerous new business purposes, including medical devices, AI healthcare, animal pharmaceuticals, pet supplies, beauty devices, and real estate development, aiming for revenue diversification. However, most new ventures currently lack investment plans or active progress, except for PDRN raw material wholesale. The report highlights the significant growth potential of the PDRN market, projected to reach 9.78T KRW by 2024, which could be a future revenue driver. The overall financial impact is neutral as the report lacks specific Q1 2026 financial performance figures and most new business initiatives are in early stages or contingent on future funding.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.